Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Business Wire•12/08/2026•09:00 ET
0
Whiz Insights
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026
Get started
Create a free account to read the full story.